Dr. Yaron Hadari

Dr. Yaron Hadari has been the Chief Executive Officer and Chief Scientific Officer of SHY Therapeutics since its founding in 2015. As explained in the History section of this site, he established the company to explore his hypothesis, since proven by SHY, that the Kd of GTP binding to Ras is in a druggable range. Encouraged by that discovery, the company embarked on the development of its portfolio of small molecules that bind non-covalently to GTPases and ATPases.

Prior to forming SHY, Yaron served as Vice President of Research at Kolltan Pharmaceuticals, where he led efforts to develop monoclonal antibody cancer therapies and worked with Mr. Schmertzler. Before his tenure at Kolltan, Yaron was Senior Director of the Cell Biology Department at ImClone Systems (acquired by Eli Lilly), overseeing early and late-stage monoclonal antibody cancer therapy programs.

In his academic career, Yaron focused on the biological roles of receptor tyrosine kinases and related signal transduction pathways.

Yaron holds an M.S. and Ph.D. from the Weizmann Institute of Science and a B.Sc. from the Hebrew University.